Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
35 Years to 55 Years (Adult)
Sexes Eligible for Study:
Subjects who are male, caucasian, and between 35 and 55 years of age, inclusive.
Subjects who have a body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive.
Subjects who have a body weight between 50 and 100 kg, inclusive.
Subjects must have regular bowel movements.
Subjects who have an abnormality in heart rate, blood pressure , temperature or 12-lead ECG.
Subjects who are still participating in a clinical study or who have participated in a clinical study involving administration of an investigational drug in the 3 months prior to dose administration.
Subjects who have had a clinically significant illness within 4 weeks of dose administration as determined by the Investigator.
Subjects who have any clinically significant abnormal laboratory safety findings.
Subjects who have had an X ray or who have participated in any clinical trial involving a radiolabelled investigational product or have been exposed to radiolabelled substances within 12 months prior to dose administration.